In conclusion, radiolabeled maxadilan accumulates efficiently and specifically in INS-1 tumors and could potentially be used for in vivo PAC1 targeting in patients with insulinoma. This evidence concerns the gene ADCYAP1R1 and pancreatic insulinoma.